Recursion Pharmaceuticals, Inc. Financials

Market Capitalization $3.12 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-4.64
Forward PE	-4.63
Price to Sales TTM	$47.79
Price to Book MRQ	$4.37
Enterprise to Revenue	30.08
Enterprise to EBITDA	-5.38

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	2.94%
Operating Margin	-377.10%
Return on Assets TTM	-36.40%
Return on Equity TTM	-78.49%

Income Statement

Revenue TTM	$65,184,000
Revenue per Share TTM	$0.27
Quarterly Revenue Growth	147.60%
Gross Profit TTM	$1,289,000
EBITDA	$-364,150,016
Net Income to Common TTM	$-377,751,008
Diluted EPS TTM	$-1.54
Quarterly Earnings Growth YoY	158.19%

Balance Sheet

Total Cash MRQ	$427,647,008
Total Cash per Share MRQ	$1.49
Total Debt MRQ	$
Total Debt to Equity MRQ	17.28
Current Ratio MRQ	4.36
Book Value per Share MRQ	$1.83

Cash Flow

Operating Cash Flow TTM	$-317,820,992
Levered Free Cash Flow TTM	$-186,334,368

RXRX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	381,900,992
Float Shares	252,423,384
Avg 10 Volume	15,212,090
Avg 30 Volume	None
Shares Short	64,573,303
Short Ratio	12.25
Short % of Shares	25.40%
% Held by Insiders	3.46%
% Held by Institutions	69.39%

Stock Price Summary

Beta	0.80
Fifty Two Week Low	$5.60
Fifty Two Week High	$15.74
Fifty Two Week Change	-46.79%
Day 50 MA	$6.62
Day 200 MA	$8.08

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date